FeNO testing in severe asthma: A clinical argument or an access constraint?

Pulmonology

Pneumology Unit, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. Electronic address:

Published: February 2022

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pulmoe.2021.05.002DOI Listing

Publication Analysis

Top Keywords

feno testing
4
testing severe
4
severe asthma
4
asthma clinical
4
clinical argument
4
argument access
4
access constraint?
4
feno
1
severe
1
asthma
1

Similar Publications

Article Synopsis
  • The study investigates the fractional exhaled nitric oxide (FeNO) levels in a healthy population to better understand normal ranges and their influencing factors.
  • FeNO levels were measured in 2,251 participants aged 6-82 years, revealing median values that increase with age and vary based on gender, height, and eosinophil counts.
  • The findings establish reference ranges for FeNO that can aid in clinical asthma diagnosis and management.
View Article and Find Full Text PDF

CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma.

Respir Res

December 2024

Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Background: Mixed granulocytic asthma (MGA) is usually associated with poor response to corticosteroid therapy and a high risk of severe asthma. Cathepsin S (CTSS) has been found to play an important role in various inflammatory diseases. This study was aimed to investigate the role of CTSS in MGA.

View Article and Find Full Text PDF

Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.

Proc (Bayl Univ Med Cent)

August 2024

North Texas Allergy and Asthma Associates and Division of Allergy/Immunology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.

Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.

View Article and Find Full Text PDF

Background: Air pollution (AP) has become a substantial environmental issue affecting human cardiorespiratory health. Physical exercise (PE) is widely accepted to promote cardiorespiratory health. There is a paucity of research on the point at which the level of polluted environment engaged in PE could be used as a preventive approach to compensate for the damages of AP.

View Article and Find Full Text PDF

Background: Fractional exhaled nitric oxide (FeNO) has been utilized as a reliable biomarker for diagnosis, treatment response, and prediction of future risks in asthma care, that potentially ensures the efficacy of FeNO-guided asthma management. As previous systematic reviews reported limited efficacy with this approach, we evaluated the efficacy of FeNO-guided management in monitoring adults with asthma.

Methods: In this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Statement and the Minds Manual for Guideline Development, we updated a Cochrane systematic review in 2016 by adding six papers reporting randomized controlled trials with a treatment duration ≥12 weeks published between June 2016 and July 2022, and conducted a sub-analysis of two groups stratified by the strategy used: the FeNO-alone and FeNO with symptom score groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!